CClinicalTrials.gg
Status unknownNCT03214978PTCUpdated Jul 12, 2017

Targeted-sequencing of PTC in Different Stages

An observational study in Exploratory Study, sponsored by Shanghai 6th People's Hospital. Status unknown. Per ClinicalTrials.gov, last updated 2017-07-12.

Sponsored by Shanghai 6th People's Hospital · Observational

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
80
Sex
All
01

Study summary

The prevalence of papillary thyroid micro-carcinoma (PTMC) increased rapidly in recent years but the design of treatment is controversial because a majority of them are indolent. Therefore, to recognize which PTMC is of strong progressive potential which should be operated is very crucial. Fine needle aspiration (FNA) pre-surgery could obtain tumor cells which could be used in genetic analysis. To date, there is no specific way to evaluate the aggressive potential of a PTMC pre-surgery. So, the purpose of this proposal is to screen genetic mutations of the aggressive type of PTMC. The candidate did a whole exome sequencing on 3-3 pairs of PTCs and found some SNPs and Indels in TP53、TTN、PDF. To further investigate those mutations, a target region sequencing will be done in 40 pairs tumor samples. And ultimately to find out which genetic event could contribute to strong aggressive potential of PTC. The mutations details would be design to test the FNA and tissue sample to validate if the genetic testing based on FNA is reliable. The gene test results would be evaluated with sonographic features to predict the potential of small thyroid carcinoma before surgery. This project won't aim to study the function and mechanism of specific genes but just screen them out. So, the fund would cover the fee of the whole study and this study is very likely to achieve the goal.

02

Conditions studied

  • Exploratory Study

Keywords

  • thyroid
03

In context

Lead sponsor

Shanghai 6th People's Hospital is the lead sponsor of 69 studies on the registry; 40 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

DNA will be extracted from of 40 pairs tumor samples including 40 patients in 4 groups (stage I, II, III and IV)

Inclusion criteria

  • patients who will receive thyroid resection

Exclusion criteria

Exclusion Criteria:

  • patients who has been radiologically treated
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
80 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. types of mutation of targets genes in papillary thyroid carcinomas in different stages

    types of mutation of targets genes in papillary thyroid carcinomas in different stages

    Time frame: 2018-1-1

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03214978
Lead sponsor
Shanghai 6th People's Hospital
Responsible party
LI Yi (Doctor, Shanghai 6th People's Hospital) — Principal investigator
First posted
Jul 12, 2017
Start date
Jul 30, 2017 (estimated)
Primary completion
Dec 1, 2017 (estimated)
Completion
Dec 31, 2017 (estimated)
Last update
Jul 12, 2017

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion